Alimta (pemetrexed) is a branded oncology product indicated for the treatment of non-small cell lung cancer and mesothelioma. Sourced from Eli Lilly for the Taiwan market, this pharmaceutical falls under the category of antineoplastic agents, commonly used in chemotherapy regimens to inhibit tumor growth by interfering with folate-dependent metabolic processes. As a branded therapeutic, it is typically procured by healthcare institutions, distributors, and oncology-focused supply chains seeking established drug formulations for cancer care.
Lotus Pharmaceutical, based in Tashkent, Uzbekistan, manufactures this product. Founded in 1966, the company operates within the pharmaceutical products category, supplying medications to international markets. Buyers evaluating this entry should note that the product’s origin and brand history may influence procurement decisions regarding regulatory compliance and market-specific availability.